Get the Stockscreener App
86.23
0.66%
-0.571
After Hours:
86.23
0.001
+0.00%
Arcellx Inc stock is traded at $86.23, with a volume of 594.97K.
It is down -0.66% in the last 24 hours and up +13.18% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$86.80
Open:
$87.38
24h Volume:
594.97K
Relative Volume:
1.15
Market Cap:
$4.78B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-28.84
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+2.19%
1M Performance:
+13.18%
6M Performance:
+45.78%
1Y Performance:
+0.03%
1-Day Range:
$85.88
$88.39
1-Week Range:
$83.33
$90.41
52-Week Range:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
86.23 | 4.81B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Trend analysis for Arcellx Inc. this weekWeekly Trading Summary & Consistent Return Investment Signals - newser.com
FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald - MarketBeat
Analyzing recovery setups for Arcellx Inc. investors2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Arcellx (NASDAQ:ACLX) Rating Lowered to Hold at Cantor Fitzgerald - MarketBeat
Automated trading signals detected on Arcellx Inc.July 2025 Update & Verified Momentum Watchlists - newser.com
Using data filters to optimize entry into Arcellx Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Is Arcellx Inc. showing signs of accumulationWeekly Market Summary & Fast Entry High Yield Tips - newser.com
Arcellx assumed with a Neutral at Cantor Fitzgerald - TipRanks
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Yahoo Finance
Arcellx's (ACLX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
ACLX: Cantor Fitzgerald Assumes Coverage with Neutral Rating | A - GuruFocus
What analyst consensus says on Arcellx Inc. stockWeekly Gains Report & Reliable Intraday Trade Plans - newser.com
Arcellx Inc Stock Analysis and ForecastIndustrial Stocks Review & Free Exceptional Market Positioning - earlytimes.in
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insider Selling: Michelle Gilson Sells 5,946 Shares of Arcellx Inc (ACLX) - GuruFocus
Arcellx CFO Gilson sells $511k in ACLX stock - Investing.com
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx (NASDAQ:ACLX) Biggest Nasdaq Stocks Mirror Biotech Progress - Kalkine Media
Could Analyst Optimism on Neurotoxicity Give Arcellx (ACLX) an Edge in CAR-T Competition? - Sahm
Will Arcellx Inc. see short term momentumEarnings Recap Summary & Growth Focused Stock Reports - newser.com
Published on: 2025-10-05 04:40:22 - newser.com
A Fresh Look at Arcellx (ACLX) Valuation Following Scotiabank’s Regulatory Optimism and CAR-T Therapy Developments - Sahm
Will Arcellx Inc. bounce back from current supportMarket Movers & Fast Entry High Yield Tips - newser.com
What moving averages say about Arcellx Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
BofA Securities Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $112 - 富途牛牛
Christopher Heery Sells 21,034 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx CMO Heery sells $5851 in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx CMO Heery sells $5851 in ACLX stock - Investing.com India
What drives Arcellx Inc stock priceEx-Dividend Date Alerts & Budget Friendly Growth - earlytimes.in
Using portfolio simulators with Arcellx Inc. includedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Arcellx CMO Heery sells $993k in ACLX stock - Investing.com India
Arcellx CMO Heery sells $993k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx (NASDAQ:ACLX) Insider Sells $993,167.52 in Stock - MarketBeat
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121 - 富途牛牛
Atle Fund Management AB Sells 18,439 Shares of Arcellx, Inc. $ACLX - MarketBeat
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval - TipRanks
Strs Ohio Acquires New Stake in Arcellx, Inc. $ACLX - MarketBeat
Christopher Heery Sells 300 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Christopher Heery Sells 3,343 Shares - MarketBeat
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcellx Inc Stock (ACLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Oct 06 '25 |
Sale |
86.22 |
1,064 |
91,733 |
13,830 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):